New insights into sickle cell disease: A disease of hypoxia

Current Opinion in Hematology

Volumn 20, Issue 3, 2013, Pages 215-221

  Sun, Kaiqi ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

adenosine signaling; heme oxygenase 1; hypoxia; nitric oxide; sickle cell disease

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; CARBON MONOXIDE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; HEME OXYGENASE 1; HEMOGLOBIN S; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE;

ARTERY ENDOTHELIUM; ERYTHROCYTE; HEMOLYSIS; HUMAN; HYPOXIA; NATURAL KILLER T CELL; NONHUMAN; PENILE FIBROSIS; PLASMODIUM; PRIAPISM; PRIORITY JOURNAL; RENAL ARTERY; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; TISSUE INJURY;

ADENOSINE; ANEMIA, SICKLE CELL; ANIMALS; ANOXIA; HEMOGLOBINS; HUMANS;

EID: 84876284584     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835f55f9     Document Type: Review

References (66)

1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med 1910; 6:517-521.
2. Pauling L, Itano HA, et al. Sickle cell anemia a molecular disease. Science 1949; 110:543-548.
3. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 1956; 178: 792-794.
4. Chang JC, Kan YW. Antenatal diagnosis of sickle cell anaemia by direct analysis of the sickle mutation. Lancet 1981; 2:1127-1129. (Pubitemid 11029638)
5. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991; 77:214-237.
6. Mucaj V, Shay JE, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol 2012; 95:464-470.
7. Maes C, Carmeliet G, Schipani E. Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev 2012; 8:358-366.
8. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148:399-408.
9. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364:656-665.
10. Fredholm BB, Ijzerman AP, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53:527-552.
11. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198:783-796. (Pubitemid 37087777)
12. Kong T, Westerman KA, Faigle M, et al. HIF-dependent induction of adenosine A2B receptor in hypoxia. Faseb J 2006; 20:2242-2250. (Pubitemid 44953854)
13. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004; 104:3986-3992. (Pubitemid 39620148)
14. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 2011; 7:281-287.
15. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 2011; 17:79-86.
16. Paszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol 1997; 4:88-93. (Pubitemid 27202123)
17. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997; 278:876-878. (Pubitemid 27467927)
18. Poillon WN, Kim BC. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 1990; 76:1028-1036. (Pubitemid 20295519)
19. Poillon WN, Kim BC, Labotka RJ, et al. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood 1995; 85:3289-3296.
20. Poillon WN, Kim BC, Welty EV, Walder JA. The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Arch Biochem Biophys 1986; 249:301-305. (Pubitemid 16023750)
21. Burnett AL. Therapy insight: priapism associated with hematologic dyscrasias. Nat Clin Pract Urol 2005; 2:449-456. (Pubitemid 41486127)
22. Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood 2007; 110:2727-2735. (Pubitemid 47523196)
23. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 2008; 5:1244-1250. (Pubitemid 351606710)
24. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106:3264-3267. (Pubitemid 41565928)
25. Abbasi S, Su B, Kellems RE, et al. The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation. J Biol Chem 2005; 280:36737-36746. (Pubitemid 41587753)
26. Yonezawa A, Sakurada S, Furukawa K, Kimura Y. Adenosine and adenosine triphosphate. Nippon Rinsho 2002; 60 (Suppl 6):52-56.
27. Noto T, Inoue H, Mochida H, Kikkawa K. Role of adenosine and P2 receptors in the penile tumescence in anesthetized dogs. Eur J Pharmacol 2001; 425:51-55. (Pubitemid 32728299)
28. Filippi S, Mancini M, Amerini S, et al. Functional adenosine receptors in human corpora cavernosa. Int J Androl 2000; 23:210-217. (Pubitemid 30479344)
29. Shalev M, Staerman F, Allain H, et al. Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum. J Urol 1999; 161:955-959. (Pubitemid 29422415)
30. Sharifzadeh M, Zarrindast MR, Samini M. Effects of adenosine analogues on apomorphine-induced penile erection in rats. Gen Pharmacol 1995; 26: 1785-1790. (Pubitemid 26033852)
31. Kilic S, Salih M, Anafarta K, et al. Adenosine: a new agent in the diagnosis of impotence. Int J Impot Res 1994; 6:191-198.
32. Hsu L, Diwan B, Ward JM, Noguchi CT. Pathology of 'Berkeley' sickle-cell mice includes gallstones and priapism. Blood 2006; 107:3414-3415.
33. Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008; 118:1491-1501. (Pubitemid 351500442)
34. Dai Y, Zhang Y, Phatarpekar P, et al. Adenosine signaling, priapism and novel therapies. J Sex Med 2009; 6 (Suppl 3):292-301.
35. Phatarpekar PV, Wen J, Xia Y. Role of adenosine signaling in penile erection and erectile disorders. J Sex Med 2010; 3:3553-3564.
36. Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med 2010; 20:3011-3022.
37. Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. Faseb J 2010; 24:740-749.
38. Wallace KL, Marshall MA, Ramos SI, et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 2009; 114:667-676.
39. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature medicine 2002; 8:1383-1389. (Pubitemid 36019423)
40. Naumann HN, Diggs LW, Barreras L, Williams BJ. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol 1971; 56:137-147.
41. Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol 2010; 224:620-625.
42. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2012; 305:893-902.
43. van Faassen EE, Bahrami S, Feelisch M, et al. Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev 2009; 29:683-741.
44. McQuillan LP, Leung GK, Marsden PA, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267 (5 Pt 2):H1921-H1927.
45. Ostergaard L, Stankevicius E, Andersen MR, et al. Diminished NO release in chronic hypoxic human endothelial cells. Am J Physiol 2007; 293:H2894-H2903. (Pubitemid 350106513)
46. Fish JE, Matouk CC, Yeboah E, et al. Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem 2007; 282:15652-15666. (Pubitemid 47093264)
47. Fish JE, Yan MS, Matouk CC, et al. Hypoxic repression of endothelial nitricoxide synthase transcription is coupled with eviction of promoter histones. J Biol Chem 2010; 285:810-826.
48. Bertrand R. Nitric oxide-mediated suppression of 2,3-bisphosphoglycerate synthesis: therapeutic relevance for environmental hypoxia and sickle cell disease. Med Hypotheses 2012; 79:315-318.
49. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 2007; 18:414-420. (Pubitemid 46193307)
50. Kanakiriya SK, Croatt AJ, Haggard JJ, et al. Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. Am J Physiol Renal Physiol 2003; 284:F546-F554. (Pubitemid 36227917)
51. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. Jj Biol Chem 1992; 267:18148-18153.
52. Seixas E, Gozzelino R, Chora A, et al. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci USA 2009; 106:15837-15842.
53. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010; 50:323-354.
54. Ferreira A, Balla J, Jeney V, et al. A central role for free heme in the pathogenesis of severe malaria: the missing link? J MolMed (Berlin, Germany) 2008; 86:1097-1111.
55. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Ann Rev Pharmacol Toxicol 2007; 47:89-116.
56. Alam J, Stewart D, Touchard C, et al. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999; 274:26071-26078.
57. Belcher JD, Mahaseth H, Welch TE, et al. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006; 116:808-816. (Pubitemid 43326890)
58. Tekin D, Dursun AD, Xi L. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacologica Sinica 2010; 31:1085-1094.
59. Nath KA, Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 2001; 158:893-903. (Pubitemid 32221782)
60. Belcher JD, Vineyard JV, Bruzzone CM, et al. Heme oxygenase-1 gene delivery by sleeping beauty inhibits vascular stasis in a murine model of sickle cell disease. J Mol Med 2011; 88:665-675.
61. Bean CJ, Boulet SL, Ellingsen D, et al. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood 2012; 120:3822-3828.
62. Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 2011; 145:398-409.
63. Kim YM, Pae HO, Park JE, et al. Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011; 14:137-167.
64. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34:1711-1720.
65. Jackson EK, Koehler M, Mi Z, et al. Possible role of adenosine deaminase in vaso-occlusive diseases. J Hypertens 1996; 14:19-29. (Pubitemid 26099513)
66. Wu ML, Ho YC, Yet SF. A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal 2011; 15:1835-1846.